Immunoglobulins D/Identified Rickettsia Tick-Borne Fever Dry

Immunoglobulins D/Identified Rickettsia Tick-Borne Fever Dry: description, application and manufacturers

Immunoglobulin D/Tick-Borne Fever Rickettsia Dry is a medication used to detect antibodies in the blood that are caused by tick-borne spotted fever rickettsia (TSF). The drug is produced in the form of a lyophilized powder, which means that it is a dry powder that must be dissolved before use.

The drug is produced by Biomed in Russia and belongs to the pharmaceutical group of immunoglobulins, which are used to treat various infectious diseases. The international name of the drug is Immunoglobulins for the detection of tick-borne spotted fever rickettsia.

Rickettsia is a group of bacteria that are transmitted to humans through the bites of infected ticks. Tick-borne spotted fever is a disease that causes fever, skin rashes and other symptoms, and can lead to serious complications if not treated promptly.

The use of immunoglobulins D/Identified Rickettsia Tick-borne Fever Dry allows you to determine the presence of antibodies in the blood that are caused by Rickettsia tick-borne spotted fever. This can be useful in diagnosing the disease and determining its stage, as well as monitoring the effectiveness of treatment.

Immunoglobulin D/Identified Rickettsia Tick-Borne Fever Dry is a safe and effective drug that can be used in the laboratory to detect antibodies in patients suspected of having RTC.

In conclusion, the drug Immunoglobulins D/Identified Rickettsia Tick-Borne Fever Dry is an important tool for the diagnosis and control of RKPL disease. Production of the drug in Russia allows us to reduce the cost and ensure accessibility for medical institutions and patients.